Safety Evaluation of THC-Free Hemp Protein Isolate

Launched by NATIONAL UNIVERSITY OF NATURAL MEDICINE · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the safety and tolerability of a hemp protein supplement that does not contain THC, which is the compound in cannabis that causes a high. The researchers want to find out if taking 20 grams of this hemp protein powder twice a day for 30 days will lead to any detectable levels of THC in urine, and if it is safe for participants' overall health, including their liver and kidney function.

To participate, you need to be a healthy adult between the ages of 18 and 65 who hasn’t used cannabis or any hemp products in the last three months. Participants in the study will take the hemp protein powder for 30 days, provide blood and urine samples at the beginning and end of the study, and complete weekly surveys about how they are feeling. This study is currently looking for volunteers, and it’s important to note that individuals with certain health issues or allergies, or those who are pregnant or breastfeeding, cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 65 years.
• • Able and willing to provide informed consent.
• • In good general health as determined by medical history and screening.
• • No cannabis or hemp product use within the past 90 days and willingness to avoid consuming other hemp-based or cannabinoid-containing products during the study period.
• • Willing to take 20 grams of hemp protein powder, twice a day, for 30 days, complete two blood draws, provide two urine samples, and fill out weekly surveys.
• Exclusion Criteria:
• • Positive THC-COOH baseline urine test.
• • Regular use of any medications that could interfere with THC metabolism.
• • History of substance abuse or dependence within the past year.
• • Individuals who are pregnant, lactating, or planning a pregnancy within the next 30 days.
• • Known allergy or hypersensitivity to cannabis, hemp, or any component of the study product.
• • Participants with chronic liver, kidney, or severe cardiovascular disease.
• • Participants with dietary restrictions that may prevent them from consuming the study product.
• • Current or recent participation in another research study within 14 days of screening.